Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort

高眼压治疗研究队列的长期生活质量

• 批准号: 10667711
• 负责人: MAE O GORDON
• 金额: $ 24.63万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667711
• 关键词: Affect; Age; Automobile Driving; Benefits and Risks; Cessation of life; Clinical; Cohort Studies; Contrast Sensitivity; Control Groups; Cross-Sectional Studies; Data; Demographic Factors; Diagnosis; Eye; Glaucoma; Health; Individual Adjustment; Individual Differences; Life; Life Expectancy; Long-Term Effects; Longitudinal cohort; Measures; National Eye Institute; Ocular Hypertension; Ophthalmology; Outcome; Participant; Patients; Primary Open Angle Glaucoma; Protocols documentation; Quality of life; Questionnaires; Reading; Reporting; Sampling; Surveys; Testing; United States Preventative Services Task Force; Vision; Visit; Visual Acuity; Visual Fields; Visual impairment; Walking; age effect; cohort; expectation; follow-up; hypertension treatment; improved; indexing; longitudinal analysis; rate of change; secondary analysis; treatment effect

Project Summary This application is for secondary analyses to determine the long-term effect of treatment, clinical and demographic factors on vision-related quality of life (VRQOL) in the Ocular Hypertension Treatment Study (OHTS) cohort. This application is timely because the US Preventative Services Task Force recently concluded there was “Inadequate evidence that treatment of primary open-angle glaucoma improves health outcomes such as reduced visual impairment, vision-related function, and quality of life” (JAMA Ophthal, May 2022). OHTS is the only US study with 20-year clinical and VRQOL outcomes in a cohort of 1,636 participants with ocular hypertension. The 20 year follow-up is meaningful because it approaches the life expectation of participants whose median age was 55 at baseline. Aim 1 will report cross-sectional 20 year data from the National Eye Institute Visual Function Questionnaire (NEI VFQ) and 15 item Glaucoma Quality Life survey (GQL-15). Aim 2 will focus on longitudinal changes in clinical and VRQOL in the inception cohort of participants who developed POAG in OHTS 1 or 2. Pre-POAG VRQOL data collected in the inception cohort will allow statistical adjustment for individual differences on post-POAG VRQOL which will increase precision of post-POAG impact on VRQOL. Accurate dates of POAG diagnosis in the inception cohort will enable a rigorous test of the effect of duration and rate of change in clinical parameters on VRQOL. We will analyze treatment, clinical and demographic factors affecting VRQOL in the cross-sectional sample at 20 years of follow-up (Aim 1) and in the longitudinal cohort sample (Aim 2). Core tests and measures were completed per protocol at 6 month intervals for 13 years and at 1-3 visits after 20 years of follow-up. Tests and measures to be analyzed include indices from Humphrey 30-2 SITA standard visual fields, best corrected acuity, Pelli-Robson contrast sensitivity, and OCT (assessed at 20 years). VRQOL was assessed using the NEI-VFQ administered every 2 years for 13 years and the GQL-15 administered at 20 years.

项目摘要 该应用是用于辅助分析以确定治疗的长期影响 与视觉相关生活质量（VRQOL）的人口统计学因素（VRQOL） 治疗研究（OHTS）队列。此应用程序是及时的，因为美国预防措施 服务工作队最近得出结论：“有证据表明治疗 原发性开角青光眼可改善健康结果，例如减少视觉障碍， 与视觉相关的功能和生活质量”（Jama Ophthal，2022年5月）。 OHTS是唯一一项具有20年临床和VRQOL结果的美国研究。 眼高血压的参与者。 20年的随访是有意义的，因为它 接近基线年龄中位年龄为55岁的参与者的生活期望。目标1意志 报告国家眼科研究所视觉功能问卷的横截面20年数据 （NEI VFQ）和15项青光眼质量寿命调查（GQL-15）。 AIM 2将重点关注 参与者的临床和VRQOL的纵向变化 在OHTS 1或2中开发的POAG。 允许对Poag后VRQOL的个体差异进行统计调整，这将 提高poag后影响对VRQOL的精度。 POAG诊断的准确日期 Inception Cohort将对临床持续时间和变化率的效果进行严格的测试 VRQOL上的参数。我们将分析影响的治疗，临床和人口统计学因素 横截面样品中的VRQOL在20年的随访中（AIM 1）和纵向 队列样本（AIM 2）。 根据协议以6个月的间隔完成核心测试和措施，持续13年，在1-3 随访20年后访问。要分析的测试和措施包括 汉弗莱（Humphrey）30-2 SITA标准视野，最佳矫正敏锐度，佩利·罗布森（Pelli-Robson）对比度 灵敏度和OCT（在20年时进行评估）。使用NEI-VFQ评估VRQOL 每2年一次管理13年，而GQL-15在20年时管理。